Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 17/20 | 0.64 |
| ▸ | CHRM2 | P08172 | 15/20 | 0.64 |
| ▸ | CHRM1 | P11229 | 15/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.48 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL4417553 | 0.99 | CHRM3 (0.66) | CHRM3CHRM2CHRM1CYP2D6CHRM4 | |
| Bromide SCHEMBL4408588 | 0.88 | CHRM3 (0.57) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Bromide SCHEMBL4416985 | 0.86 | CHRM3 (0.61) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Bromide SCHEMBL4408398 | 0.85 | CHRM3 (0.66) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Bromide SCHEMBL4415242 | 0.82 | CHRM3 (0.70) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Bromide SCHEMBL4412472 | 0.82 | CHRM3 (0.57) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Bromide SCHEMBL4407438 | 0.80 | CHRM3 (0.51) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL2929813 | 0.80 | CHRM3 (0.45) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL2929814 | 0.80 | CHRM3 (0.51) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Bromide SCHEMBL2799406 | 0.80 | CHRM3 (0.45) | CHRM3CHRM2CHRM1CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090326004-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-12-31 | — | — | US | disclosed |
| EP-2130830-A1 | Muscarinic receptor antagonists | Ranbaxy Laboratories Limited (IN) | 2009-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326004-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | LTB4R2, LTB4R, LTC4S | CHRM3 7/4885CHRM2 11/4885CHRM1 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.